Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation

Clinical Transplantation

Volumn 26, Issue 5, 2012, Pages

  Kikuchi, Taku ^a   Mori, Takehiko ^a   Yamane, Akiko ^a   Kato, Jun ^a   Kohashi, Sumiko ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclosporine A; Drug interaction; Fungal infection; Hematopoietic stem cell transplantation; Voriconazole

Indexed keywords

CYCLOSPORIN A; VORICONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES; YOUNG ADULT;

EID: 84867622476     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12016     Document Type: Article

References (22)

1. Dykewicz CA, Jaffe HW. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006: 6: 670.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002: 34: 909.
3. Kami M, Machida U, Okuzumi K et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002: 117: 40.
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002: 347: 408.
5. Jeu L, Piacenti FJ, Lyakhovetskiy AG et al. Voriconazole. Clin Ther 2003: 25: 1321.
6. Herbrecht R, Fluckiger U, Gachot B et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007: 5: 49.
7. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008: 46: 327.
8. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006: 26: 1730.
9. Romero AJ, Le Pogamp P, Nilsson LG et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002: 71: 226.
10. Wood N, Tank K, Allan R et al. Effect of voriconazole on the pharmacokinetics of tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 22-5 September 2001 (abstract A-20). American Society of Microbiology, Washington, DC, 2001.
11. Pfizer Inc. Vfend (Voriconazole) Package Insert. New York, NY: Pfizer Inc., 2010.
12. Mori T, Aisa Y, Kato J et al. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009: 44: 371.
13. Mori T, Kato J, Yamane A et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol 2012: 95: 564.
14. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997: 691: 441.
15. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002: 42: 395.
16. Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005: 35: 509.
17. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006: 50: 1570.
18. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007: 109: 1532.
19. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008: 46: 201.
20. Brüggemann RJ, Blijlevens NM, Burger DM et al. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2010: 65: 107.
21. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000: 38: 41.
22. Lown KS, Kolars JC, Thummel KE et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994: 22: 947.